Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.50 |
| ▸ | DRD3 | P35462 | 6/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10008510 | 0.83 | FUCA1 (0.56) | FUCA1P2RY14 | |
| SCHEMBL5406788 | 0.83 | DRD3 (0.47) | DRD2DRD3CHRM3OPRM1ARRB1 | |
| SCHEMBL5402545 | 0.83 | OPRM1 (0.54) | DRD2DRD3CHRM3OPRM1FUCA1 | |
| SCHEMBL5399533 | 0.81 | FUCA1 (0.46) | FUCA1P2RY14 | |
| SCHEMBL5394580 | 0.81 | FUCA1 (0.46) | DRD2CHRM3OPRM1FUCA1P2RY14 | |
| SCHEMBL5742361 | 0.81 | BCHE (0.47) | CHRM3FUCA1P2RY14 | |
| SCHEMBL5742358 | 0.81 | FUCA1 (0.46) | OPRM1FUCA1P2RY14 | |
| SCHEMBL21238092 | 0.79 | OPRM1 (0.48) | DRD2DRD3CHRM3OPRM1 | |
| SCHEMBL21220270 | 0.79 | OPRM1 (0.48) | DRD2DRD3CHRM3OPRM1 | |
| SCHEMBL21220273 | 0.79 | OPRM1 (0.48) | DRD2DRD3CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241887-B2 | 3-azabicyclo[3.2.1]octane derivatives | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1615894-A2 | 3-AZABICYCLO 3.2.1 OCTANE DERIVATIVES | Pfizer Products Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| WO-2004089908-A2 | 3-AZABICYCLO[3.2.1]OCTANE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | OPRD1, OPRK1, OPRM1 | DRD2 35/4885DRD3 24/4885CHRM3 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.